Pipamperone/antipsychotics

Drug Profile

Pipamperone/antipsychotics

Alternative Names: Clozapine/pipamperone; Paliperidone/pipamperone; Pipamperone/clozapine; Pipamperone/paliperidone; Pipamperone/risperidone; PNB-02; Risperidone/pipamperone

Latest Information Update: 22 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PharmaNeuroBoost
  • Class Antipsychotics; Butyrophenones; Isonipecotic acids; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Schizoaffective disorder; Schizophrenia

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Schizophrenia (Combination therapy) in Belgium (PO)
  • 21 Dec 2012 PharmaNeuroBoost completes a phase I/IIa trial in Schizophrenia in Belgium (NCT01450514)
  • 01 Mar 2012 Phase-I/II clinical trials in Schizophrenia in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top